Veeda Clinical Research Limited Unlisted Share Price
Veeda Clinical Research Limited unlisted share price is ₹428 per share (indicative, as of 18 Oct 2026). Minimum ticket ₹25,000 (lot of 59 shares), the same for every company. Sector: Consumer. Status: DRHP filed with SEBI, IPO awaited.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 18 Oct 2026, 13:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; Veeda Clinical Research Limited’s indicative price is ₹428 per share as of 18 Oct 2026, a lot of 59 shares.
Key facts
- Indicative price
- ₹428 per share
- Price as of
- 18 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 59 shares
- Sector
- Consumer
- DRHP
- Filed with SEBI on 31 Jan 2025
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 18 Oct 2026, 13:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 18 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE01HQ01026: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- DRHP filed with SEBI on 31 Jan 2025; the IPO has not opened yet.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative move: 0.0% over 3 months · -7.0% over 1 year.
Key figures
| Market cap | ₹2,815 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 59 |
| P/E ratio | — |
| ROE | -7.77% |
| Book value | ₹131.38 |
| Face value | ₹2 |
| 52-week high | ₹460 |
| 52-week low | ₹428 |
| ISIN | INE01HQ01026 |
| Dividend yield | — |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 410 | 389 | 610 |
| PAT | 45.1 | -0.36 | -66.8 |
| EPS (₹) | 7.58 | -0.04 | -10.6 |
About the company
Veeda Clinical Research Limited is an India-based contract research organisation (CRO) incorporated in 2004 and headquartered in Ahmedabad, Gujarat. The company provides end-to-end clinical research services to the pharmaceutical and biotechnology industry, spanning bioavailability and bioequivalence (BA/BE) studies, pre-clinical testing, early and late-phase clinical trials, bioanalytical work…
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Ahmedabad, Gujarat.
Registry
- ISIN: INE01HQ01026
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 18 Oct 2026
Company facts
| CIN | U73100GJ2004PLC044023 |
|---|---|
| Incorporated | 2004 |
| ISIN | INE01HQ01026 |
| Face value | ₹2 |
| Registered office | Shivalik Plaza-A, 2nd Floor, Opp. Ahmedabad Management Association, Ambawadi, Ahmedabad, Gujarat 380015, India |
| Shares outstanding | 65,77,74,95,658 |
| Lot size | 59 shares |
| Minimum units | 25 |
| DRHP | Filed · 31 Jan 2025 |
Financial statements (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 vs FY25 |
|---|---|---|---|---|---|---|
| Revenue | 293.1 | 409.58 | 388.78 | 609.73 | 715.5 | +17.3% |
| EBITDA | — | 103 | 53 | 125 | 209.6 | +67.7% |
| Profit before tax | — | 59 | 3.3 | −66 | 7.3 | loss to profit |
| Profit after tax | 50.46 | 45.09 | −0.36 | −66.81 | −14 | +79% |
| EPS (₹) | 10.26 | 7.58 | −0.04 | −10.57 | −2 | +81.1% |
| Net margin | — | — | −0.1% | −11% | — | — |
| Share capital | — | — | 12.6 | 13.16 | — | — |
| Reserves & surplus | — | — | 1,047.37 | 842.6 | — | — |
| Net worth | — | — | 1,059.97 | 855.76 | — | — |
| Trade receivables | — | — | 120.9 | 77.13 | — | — |
| Trade payables | — | — | 65.48 | 47.6 | — | — |
| Cash from operations | — | — | 58.89 | 33.32 | — | — |
| Cash from investing | — | — | −446.91 | −149.31 | — | — |
| Cash from financing | — | — | 399.65 | 91.41 | — | — |
| Net cash generated | — | — | 11.64 | −24.58 | — | — |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹428 | dealer reference, 18 Oct 2026 |
| Market cap | ₹2,815 Cr | as recorded |
| P/E | — | loss-making, n/a |
| P/B | 3.26x | price ÷ book value ₹131.38 |
| EPS | ₹−2 | per share, FY26 |
| Book value | ₹131.38 | per share, latest books |
| RoE | −7.77% | return on equity, latest FY |
| Debt / equity | 0.47 | latest balance sheet |
| Dividend yield | — | |
| Face value | ₹2 | per share |
| 52-week range | ₹428 – ₹460 | 317 dated quotes, last 12 months |
| Shares outstanding | 65,77,74,95,658 | per company record |
Shareholding pattern
| Category | Holder | % of equity |
|---|---|---|
| Promoters | Promoters | 33.83% |
| Public | Public | 66.17% |
Promoters 33.83% · Public 66.17%
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Dr. Mahesh Bhalgat | Managing Director & CEO | — |
| Nitin Deshmukh | Chairman | — |
| Binoy Gardi | Whole-time Director | — |
| Nirmal Bhatia | Company Secretary & CFO | — |
Business model
Veeda Lifesciences is a global contract research organisation that supplies clinical, preclinical and bioanalytical services to drug-development clients. Its issuer website says the business supports innovative, biosimilar and generic drugs. The cited service scope includes preclinical R&D, bioequivalence and bioavailability studies, bioanalytical work and early- to late-phase clinical trials from Phase I through Phase IV. Veeda says it operates across multiple regions and works with clients during drug-development programs rather than selling therapeutic products.
Its stated operating focus is scientific research execution, regulatory compliance and ethical practices, supported by investment in people, processes and technology. The company describes its mission as delivering science-based, technology-led and client-specific solutions, with execution capabilities across geographies. Its website also identifies real-world data and AI as tools it intends to use in supporting development programs. This description excludes promotional performance claims and forward-looking estimates.
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Undated | Merger | The Board approved subscription for and acquisition of Bioneeds India Private Limited equity shares; shareholder approval followed on 26 May 2022. (24 May 2022) | — | Desk note |
| Undated | Merger | The Board approved acquisition of a further 3.03% stake in Bioneeds India Private Limited. (18 Nov 2022) | — | Desk note |
| Undated | Other | The Board resolved to raise INR 1,943.94 million from identified investors by preferential allotment on a private-placement basis. (18 Mar 2023) | — | Desk note |
| Undated | Merger | The Board resolved to acquire the remaining 50% shares of Ingenuity Biosciences Private Limited. (12 May 2023) | — | Desk note |
Reports and filings
No filings uploaded yet.
Annual reports
- Veeda Clinical Research Limited annual report 2024-25 (PDF)
- Veeda Clinical Research Limited annual report 2024-25 (PDF)
- Veeda Clinical Research Limited annual report 2023-24 (PDF)
- Veeda Clinical Research Limited annual report 2022-23 (PDF)
Frequently asked questions
What does Veeda Clinical Research Limited do?
Veeda Clinical Research Limited is an India-based contract research organisation (CRO) incorporated in 2004 and headquartered in Ahmedabad. It provides clinical research services to pharmaceutical and biotech companies, including bioavailability and bioequivalence (BA/BE) studies, pre-clinical and clinical trials, bioanalytical services, pharmacovigilance, and medical writing.
Is Veeda Clinical Research Limited listed on the stock exchanges?
No. Veeda Clinical Research Limited is currently an unlisted company, and its shares trade in the private, unlisted market. The company has filed a draft red herring prospectus (DRHP) with SEBI for a proposed IPO, but the listing has not yet taken place. Whether or when an IPO proceeds is not certain.
How can I buy Veeda Clinical Research Limited unlisted shares?
Unlisted shares are transacted privately and credited to your demat account rather than through an exchange order book. To understand the current process and availability, you can contact the desk for assistance.
What are the risks of holding Veeda Clinical Research Limited unlisted shares?
Unlisted and pre-IPO shares carry higher risk and lower liquidity than listed shares. Prices are indicative and can change sharply, there is no certainty that an IPO will occur or proceed on any particular timeline, exit options may be limited, and the company's financial performance can fluctuate. Conduct your own due diligence before making any decision.
What is the Veeda Clinical Research Limited unlisted share price today?
The indicative over-the-counter reference price is ₹428 per share as of 18 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is Veeda Clinical Research Limited listed on a stock exchange?
Not yet. The company has an IPO in progress: DRHP filed. Until listing, shares change hands over the counter and settle into your demat account.
What is the minimum investment in Veeda Clinical Research Limited?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of Veeda Clinical Research Limited?
INE01HQ01026. Holdings are settled in demat form through NSDL and CDSL.
How do I buy Veeda Clinical Research Limited unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if Veeda Clinical Research Limited lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- Veeda Clinical Research Limited annual report 2024-25 · FY 2024-25 · veedalifesciences.com
- Veeda Clinical Research Limited annual report 2024-25 · FY 2024-25 · veedalifesciences.com
- Veeda Clinical Research Limited annual report 2023-24 · FY 2023-24 · veedalifesciences.com
- Veeda Clinical Research Limited annual report 2022-23 · FY 2022-23 · veedalifesciences.com
- Draft offer document on record · 31 Jan 2025 · sebi.gov.in
- BuyUnlistedShares indicative price series for Veeda Clinical Research Limited, dated daily · since 13 Sep 2025 (343 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Veeda Clinical Research Limited unlisted share price”, https://buyunlistedshares.com/unlisted-shares/veeda-clinical-research-limited, as of 18 Oct 2026.
Other Consumer unlisted shares
- A V Thomas & Co. Limited · ₹12,500
- Anglo French Drugs and Industries · ₹1,075
- Anheuser Busch Inbev India (AB InBev) · ₹555
- Apollo Fashion International · ₹44
- Arch Pharmalabs Limited · ₹85
- Auckland Jute Co. Limited · ₹189
Enquire to buy Veeda Clinical Research Limited · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 18 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
